Monday, 22 June 2015

Psoriatic Arthritis Pharmacotherapy Market Segment Forecasts up to 2020, Research Reports

Psoriatic Arthritis is a type of chronic inflammatory arthritis that primarily affects toes and fingers followed by nail or skin psoriasis. The clinical features are varied but the major symptoms are peripheral arthritis, enthesitis, psoriasis, dactylitis and axial disease. According to Arthritis Foundation, the prevalence of psoriatic arthritis in patients suffering from psoriasis is approximately between 7% and 48%. Psoriatic arthritis appears most often between the age of 30 years and 50 years. The factors contributing to the pathogenesis of psoriatic arthritis are genetic factors, environmental factors and immunological factors. Genetic factors explain that 40% of the psoriatic arthritis has family history of skin and joint diseases. Environmental factors such as bacterial and viral infections have been implicated as a cause in psoriatic arthritis. Immunological factors consist of cytokines such as TNF-α which is critically involved in inflammatory process, leading to bone and cartilage degradation as well as skin inflammation. There are five different types of psoriatic arthritis that includes different joints and spinal column. There are two types of method by which psoriatic arthritis is diagnosed by imaging and laboratory test. Imaging tests consist of X-Rays and magnetic resonance imaging and laboratories consists of rheumatoid factor and joint fluid test.

The pharmacotherapy of psoriatic arthritis consists of drugs such as DMARDs (disease modifying anti-rheumatic drugs), NSAIDs, Immunosuppressant and TNF-α inhibitors. In chronic conditions surgeries and other procedures are practiced such as steroid injections and joint replacement surgery. The DMARDs consists of drug that reduces the progression of psoriatic arthritis and protect joints and other tissues from irreversible damage, it includes drugs such as methotrexate, sulfasalazine and leflunomide. The NSAIDs help to relive the pain and reduction of inflammation and most of them are OTC drugs including Ibuprofen and naproxen sodium. While immunosuppressant helps to control the immune system including azathioprine and cyclosporine. TNF-α inhibitors assist reducing pain, swollen joints and morning stiffness this class of drug includes etanercept, infliximab, adalimumab, Humira, certolizumab and golimumab.

Some of the major factors driving the psoriatic arthritis market are rising geriatric population, increasing incidences of psoriatic arthritis and major onset for growth in this market is expected from the launch of blockbuster drugs such as Simponi and Vicodin along with many impending biologics that are in late stage of development. The major factors restraining the growth of psoriatic arthritis pharmacotherapy market are the new biologics that are observed to be highly efficient but come with high cost. Lack of patient awareness is one of the major factor affecting the growth of psoriatic arthritis pharmacotherapy market according to CDC (Center of Disease Control and Prevention) nearly 10% - 12% of the patients visit clinics during the chronic stage of psoriatic arthritis as most of them ignore initial symptoms which are very common like skin reddening along with a joint pain or a skin rash.

North America was observed to be the leading geography due to high prevalence of psoriatic arthritis followed by availability of modern healthcare facilities is assisting the growth of this market. Europe is the second largest market for psoriatic arthritis pharmacotherapy as it’s the region expected to observe rapid aging population. Asia-Pacific and Rest of the World are the most attractive and growing markets in psoriatic arthritis pharmacotherapy. In Asia-Pacific China, India, Japan, South Korea and Australia are observed to be the leading geographies in psoriatic arthritis.

The psoriatic arthritis pharmacotherapy market is predominantly led by the players such as Pfizer, Inc., Amgen, Inc., Merck & Co, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Abbott Laboratories and Novartis International AG. It was observed that Abbott Laboratories, Johnson and Johnson and Amgen, Inc. account for the major market share in psoriatic arthritis pharmacotherapy.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa
  • Latin America
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Pharmaceutical Market: 

About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Inquiry Before Buying: 

Contact Us

Mr. Nachiket Ghumare
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States.

Browse market research blog:

No comments:

Post a Comment